市場調査レポート
商品コード
1450991
等温核酸増幅技術(INAAT)市場レポート:製品、技術、用途、エンドユーザー、地域別、2024-2032Isothermal Nucleic Acid Amplification Technology Market Report by Product, Technology, Application, End-User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
等温核酸増幅技術(INAAT)市場レポート:製品、技術、用途、エンドユーザー、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2~3営業日
|
世界の等温核酸増幅技術(INAAT)市場規模は2023年に31億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに79億米ドルに達し、2024年から2032年の間に10.8%の成長率(CAGR)を示すと予測しています。
等温核酸増幅技術(INAAT)は、分子生物学や組み換えDNA技術において、核酸の検出や同定に用いられます。一定の温度で核酸を増幅するのが一般的で、サーモサイクラー装置が不要になります。主にRNA、DNA、細胞、タンパク質、低分子、イオンに利用され、遺伝性疾患、遺伝性疾患、感染性疾患を迅速、高感度、正確に診断することができます。多用途の核酸ナノ材料の製造に使用されるアンプリコンを生成します。これに加えて、(HIV)、結核、インフルエンザ、A型肝炎、B型肝炎、クラミジア、淋病(CT/NG)など、さまざまな感染症の検出にも役立っています。その結果、INAATは世界中で絶大な支持を得ています。
コロナウイルス病(COVID-19)を検出するINAATの開発が進んでいることは、市場にプラスの影響を与えている主な要因の一つです。これに伴い、世界の老年人口の増加、がんやその他の慢性疾患の有病率の上昇、効率的な診断や治療法に対する需要の高まりが、市場の成長に寄与しています。これとは別に、DNAやRNAを増幅するためのループ媒介等温増幅(LAMP)検査の採用や遺伝子組み換え生物(GMO)の同定が、INAATの需要を刺激しています。さらに、鎖置換増幅法(SDA)、シングル・プライマー等温増幅法(SPIA)、組換えポリメラーゼ増幅法(RPA)の開発が、もう一つの成長促進要因として作用しています。さらに、新興国市場をリードする企業による研究開発(R&D)活動への投資の増加が市場を牽引すると予測されています。
The global isothermal nucleic acid amplification technology (INAAT) market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.9 Billion by 2032, exhibiting a growth rate (CAGR) of 10.8% during 2024-2032.
The isothermal nucleic acid amplification technology (INAAT) is used in molecular biology and recombinant DNA technologies for detecting and identifying nucleic acids. It is commonly used to amplify nucleic acids at a constant temperature, thereby eliminating the need for thermocycler equipment. It is majorly utilized for RNA, DNA, cells, proteins, small molecules, and ions to ensure the rapid, sensitive and accurate diagnosis of genetic, inherited, and infectious diseases. It generates amplicons that are employed in producing versatile nucleic acid nanomaterials. Besides this, it assists in detecting various infectious diseases, such as (HIV), tuberculosis, influenza, hepatitis A and B, chlamydia, and gonorrhea (CT/NG). As a result, INAAT is gaining immense traction across the globe.
The ongoing development in INAAT for detecting coronavirus disease (COVID-19) represents one of the key factors positively influencing the market. In line with this, the increasing geriatric population globally and the rising prevalence of cancer and other chronic medical disorders, along with the escalating demand for efficient diagnosis and treatment alternatives, are contributing to the market growth. Apart from this, the adoption of loop-mediated isothermal amplification (LAMP) tests to amplify DNA and RNA and the identification of genetically modified organisms (GMOs) is catalyzing the demand for INAAT. Furthermore, the development of strand displacement amplification (SDA), single primer isothermal amplification (SPIA), and recombinase polymerase amplification (RPA) are acting as another growth-inducing factor. Moreover, increasing investments in research and development (R&D) activities by leading market players are projected to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global isothermal nucleic acid amplification technology market report, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, technology, application, and end-user.
Instruments
Reagents
Reagents hold the majority of the global isothermal nucleic acid amplification technology market share due to their increasing use in therapeutics.
Helicase-Dependent Amplification (HDA)
Nicking Enzyme Amplification Reaction (NEAR)
Loop-Mediated Isothermal Amplification (LAMP)
Strand Displacement Amplification (SDA)
Nucleic Acid Sequence-Based Amplification (NASBA)
Transcription Mediated Amplification (TMA)
Single Primer Isothermal Amplification (SPIA)
Others
TMA accounts for the majority of the total market share as it allows a clinical laboratory to perform nucleic acid test (NAT) assays for blood screening with fewer steps and less processing time.
Infectious Disease Diagnosis
Hepatitis
CT/NG
HIV
Influenza
Others
Blood Screening
Others
Infectious disease diagnosis currently dominates the market due to the rising prevalence of infectious diseases across the globe.
Hospitals
Diagnostic Laboratories
Research Laboratories
Others
Hospitals presently dominate the market due to the increasing number of hospitals and significant development in the healthcare industry.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market due to the shifting consumer preference for INAAT testing over traditional diagnostic procedures.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Abbott Laboratories, bioMerieux SA, Becton, Dickinson and Company, Eiken Chemical Co. Ltd., Hologic Inc., Meridian Bioscience Inc., OptiGene Limited, Thermo Fisher Scientific Inc., Tecan Trading AG, and Ustar Biotechnologies Ltd.